Subvenite Suspension
Product Images NDC 69102-418

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Subvenite (NDC 69102-418). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Owp Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (Carton Label Page 1)

Packaging label for SUBVENITE (lamotrigine) oral suspension, 10 mg/mL, by OWP Pharmaceuticals, Inc. The label indicates a 240 mL bottle, cherry-flavored suspension with sucralose, suitable for ketogenic diets. Warnings include shaking well before use and keeping out of reach of children. Storage, discard, and dosage instructions are noted.*

FDA Label Image

Container (Container Label)

Label for Subvenite (lamotrigine) oral suspension, 10 mg/mL, by OWP Pharmaceuticals, Inc. The 240 mL bottle label includes a NDC number (69102-418-01), storage instructions, warnings, and a note to shake well before use. It advises discarding unused product 90 days after opening and dispensing the medication guide with each patient.*

FDA Label Image

Figure-1 (Figure 1 Subvenite 1)

A line graph depicting failure probability (%) over weeks (0 to 90+) comparing lamotrigine and placebo groups. Two Kaplan-Meier curves show that failure probability increases over time for both treatments, with placebo consistently higher than lamotrigine. Censoring events are marked on both curves.*

FDA Label Image

Figure-2 (Figure 2 Subvenite 1)

A line graph depicting failure probability (%) over 80 weeks comparing Lamotrigine and Placebo. The X-axis represents weeks, and the Y-axis shows failure probability percentage. The graph includes censored data points and illustrates trends of failure probabilities for both treatment groups over time.*

FDA Label Image

Owp Logo (Logo Owp)

FDA Label Image

Structure (Structure 1)

Chemical structure diagram of lamotrigine, the active ingredient in SUBVENITE oral suspension. The structure features a triazine ring connected to a chlorinated phenyl group and an amino substituent, illustrating the molecular arrangement of lamotrigine.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.